Stuart R. Dalziel
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Stuart R. Dalziel has a total of 398 co-authors. Here are the top co-authors by number of shared publications:
- Franz E. Babl
Departments of Paediatrics and Critical Care The University of Melbourne Parkville Victoria Australia
30 shared publications - Meredith Louise Borland
Emergency Department, Perth Children’s Hospital, Nedlands, Western Australia, Australia
16 shared publications - Ed Oakley
Department of Paediatrics University of Melbourne Parkville Victoria Australia
14 shared publications - Shane George
Emergency Department, Gold Coast University Hospital, Southport, Queensland, Australia
10 shared publications - Simon Craig
Emergency Department, Monash Children's Hospital, Clayton, Victoria, Australia
10 shared publications - Catherine L. Wilson
Clinical Sciences Murdoch Children's Research Institute Parkville Victoria Australia
8 shared publications
Latest Publications
- 14 September 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Secondary analysis of the 2021–2023 Sepsis Epidemiology in Australian and New Zealand Children Observational Dataset: Association Between Presenting Venous Lactate Concentration and 72-Hour Outcomes
Objectives: In pediatric patients with sepsis, we hypothesized that the initial venous lactate concentration would be associated with subsequent need for extracorporeal life support (ECLS) or death within 72 hours. Design: A planned secondary analysis of data from the multicenter, two-country Sepsis Epidemiology Emergency Departments (SENTINEL) study, collected 2021–2023. Setting: Acute care hospitals in Australia and New Zealand. Patients: SENTINEL participants were children of 0 to less than 18 years with suspected sepsis admitted to the hospital through 11 emergency departments. Interventions: None. Measurements and Main Results: We used the initial venous lactate concentration (sampling within 4 hr of hospital arrival) as an explanatory variable for subsequent need for ECLS or death within 72 hours. In 4806 children, with a median (interquartile range [IQR]) age of 1.9 years (IQR, 0.2–6.7 yr), 2651 children (55.2%) were males, and 33 children (0.7%) received ECLS or died within 72 hours. The best-performing initial lactate concentration associated with ECLS or death within 72 hours was 3.5 mmol/L and was observed in 745 of 4806 children (15.5%), including 24 of 33 children requiring ECLS or who died within 72 hours. As a “diagnostic” test, lactate greater than or equal to 3.5 mmol/L had sensitivity (95% CI) of 72.7% (95% CI, 54.5–86.7%), specificity of 84.9% (95% CI, 83.9–85.9%), and area under the receiver-operating characteristics curve of 0.79 (95% CI, 0.71–0.87) for ECLS or death within 72 hours, which are in the acceptable-to-fair category. That is, a 4-hour lactate concentration greater than or equal to 3.5 mmol/L takes the pre- to posttest probability of ECLS/death from 0.7% to 3.2%. Conclusions: In this secondary analysis of the 2021–2023 SENTINEL dataset, we have found that at the time children are hospitalized with suspected community-acquired sepsis, an initial venous lactate greater than or equal to 3.5 mmol/L has an acceptable-to-fair association with subsequent need for ECLS, or death, within 72 hours. Clinicians will need to decide whether such testing on its own is useful in decision-making.
- 14 September 2026
- Published by Wolters Kluwer Health in Pediatric Critical Care Medicine
Secondary analysis of the 2021–2023 Sepsis Epidemiology in Australian and New Zealand Children Observational Dataset: Association Between Presenting Venous Lactate Concentration and 72-Hour Outcomes
Objectives: In pediatric patients with sepsis, we hypothesized that the initial venous lactate concentration would be associated with subsequent need for extracorporeal life support (ECLS) or death within 72 hours. Design: A planned secondary analysis of data from the multicenter, two-country Sepsis Epidemiology Emergency Departments (SENTINEL) study, collected 2021–2023. Setting: Acute care hospitals in Australia and New Zealand. Patients: SENTINEL participants were children of 0 to less than 18 years with suspected sepsis admitted to the hospital through 11 emergency departments. Interventions: None. Measurements and Main Results: We used the initial venous lactate concentration (sampling within 4 hr of hospital arrival) as an explanatory variable for subsequent need for ECLS or death within 72 hours. In 4806 children, with a median (interquartile range [IQR]) age of 1.9 years (IQR, 0.2–6.7 yr), 2651 children (55.2%) were males, and 33 children (0.7%) received ECLS or died within 72 hours. The best-performing initial lactate concentration associated with ECLS or death within 72 hours was 3.5 mmol/L and was observed in 745 of 4806 children (15.5%), including 24 of 33 children requiring ECLS or who died within 72 hours. As a “diagnostic” test, lactate greater than or equal to 3.5 mmol/L had sensitivity (95% CI) of 72.7% (95% CI, 54.5–86.7%), specificity of 84.9% (95% CI, 83.9–85.9%), and area under the receiver-operating characteristics curve of 0.79 (95% CI, 0.71–0.87) for ECLS or death within 72 hours, which are in the acceptable-to-fair category. That is, a 4-hour lactate concentration greater than or equal to 3.5 mmol/L takes the pre- to posttest probability of ECLS/death from 0.7% to 3.2%. Conclusions: In this secondary analysis of the 2021–2023 SENTINEL dataset, we have found that at the time children are hospitalized with suspected community-acquired sepsis, an initial venous lactate greater than or equal to 3.5 mmol/L has an acceptable-to-fair association with subsequent need for ECLS, or death, within 72 hours. Clinicians will need to decide whether such testing on its own is useful in decision-making.
- 15 June 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 297, 115195
Guideline-Discordant Bronchiolitis Care in Community Emergency Departments
- 15 June 2026
- Published by Elsevier in The Journal of Pediatrics
- Vol. 297, 115195
Guideline-Discordant Bronchiolitis Care in Community Emergency Departments
- Open Access
- 30 March 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (4) , e71582
Investigations for Bronchiolitis in Infants: An Overview of Reviews and Systematic Review of Primary Studies
Aim: To synthesize evidence on the clinical utility of chest X‐ray (CXR), laboratory and viral testing in infants with bronchiolitis, including in subgroups with unexpected deterioration or intensive care unit (ICU) admission (severe disease). Methods: An overview of reviews and systematic review of primary studies were conducted. MEDLINE, EMBASE, PubMed, Cochrane Library, CINAHL were searched (2000 to 19/02/25) for systematic reviews and primary studies evaluating investigations in bronchiolitis management at hospital. Risk of bias (ROBIS, NOS) and certainty of evidence (GRADE) were evaluated. Results were narratively synthesized. Results: Thirty/28,602 publications were included ( N = 23,605 infants, N = 59 studies; three systematic reviews [32 studies], 27 observational studies). In typical bronchiolitis: (1) CXR demonstrated insufficient diagnostic accuracy, increased antibiotic prescriptions, and was not associated with ICU length of stay (LOS) (very low quality of evidence); (2) Laboratory test results were not associated with mortality, and were inconsistent for LOS (very low quality of evidence); (3) Viral testing results were not associated with ICU admission, and were inconsistent for hospitalization (very low quality of evidence). In infants with severe disease: serum procalcitonin and c‐reactive protein testing at ICU admission had some benefit in predicting bacterial co‐infection and/or pneumonia (very low quality evidence). Evidence was lacking for infants with unexpected deterioration. Conclusions: Very low certainty evidence indicates that CXR, laboratory and viral testing may have limited clinical utility in individual management of typical bronchiolitis, and should not be routinely used in this group. Further research is required in subgroups with unexpected deterioration or severe disease.
- 30 March 2026
- Published by Wiley in Pediatric Pulmonology
- Vol. 61 (4) , e71582
Open AccessInvestigations for Bronchiolitis in Infants: An Overview of Reviews and Systematic Review of Primary Studies
Aim: To synthesize evidence on the clinical utility of chest X‐ray (CXR), laboratory and viral testing in infants with bronchiolitis, including in subgroups with unexpected deterioration or intensive care unit (ICU) admission (severe disease). Methods: An overview of reviews and systematic review of primary studies were conducted. MEDLINE, EMBASE, PubMed, Cochrane Library, CINAHL were searched (2000 to 19/02/25) for systematic reviews and primary studies evaluating investigations in bronchiolitis management at hospital. Risk of bias (ROBIS, NOS) and certainty of evidence (GRADE) were evaluated. Results were narratively synthesized. Results: Thirty/28,602 publications were included ( N = 23,605 infants, N = 59 studies; three systematic reviews [32 studies], 27 observational studies). In typical bronchiolitis: (1) CXR demonstrated insufficient diagnostic accuracy, increased antibiotic prescriptions, and was not associated with ICU length of stay (LOS) (very low quality of evidence); (2) Laboratory test results were not associated with mortality, and were inconsistent for LOS (very low quality of evidence); (3) Viral testing results were not associated with ICU admission, and were inconsistent for hospitalization (very low quality of evidence). In infants with severe disease: serum procalcitonin and c‐reactive protein testing at ICU admission had some benefit in predicting bacterial co‐infection and/or pneumonia (very low quality evidence). Evidence was lacking for infants with unexpected deterioration. Conclusions: Very low certainty evidence indicates that CXR, laboratory and viral testing may have limited clinical utility in individual management of typical bronchiolitis, and should not be routinely used in this group. Further research is required in subgroups with unexpected deterioration or severe disease.
- 27 January 2026
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 10 (3) , 156-166
Paracetamol versus ibuprofen as required for fever or pain in the first year of life and the risk of eczema and bronchiolitis at age 1 year in New Zealand (PIPPA Tamariki): a multicentre, open-label, parallel-group, superiority, randomised controlled trial
- 27 January 2026
- Published by Elsevier in The Lancet Child & Adolescent Health
- Vol. 10 (3) , 156-166
Paracetamol versus ibuprofen as required for fever or pain in the first year of life and the risk of eczema and bronchiolitis at age 1 year in New Zealand (PIPPA Tamariki): a multicentre, open-label, parallel-group, superiority, randomised controlled trial
- Open Access
- 12 January 2026
- Published by Wolters Kluwer Health in Pediatric Emergency Care
- Vol. 42 (3) , 209-217
Suspected Pediatric Appendicitis Management in the Emergency Department
Objective: Abdominal pain is a common pediatric presentation in the emergency department (ED), and acute appendicitis (AA) is the most common surgical diagnosis. This study describes the management of suspected AA in a tertiary Australian pediatric ED. Methods: A single-center prospective observational study was performed between November 2022 and May 2023. Children aged 5 to 15 years presenting to the ED with acute abdominal pain and clinician suspicion of AA were included. Clinical gestalt was measured using a 5-point Likert Scale before and after blood tests. Diagnosis of AA was confirmed on histopathology, and non-AA was confirmed with follow-up at 30 to 60 days. Results: The study enrolled 481 children; AA was diagnosed in 146 (30.6%). Patients with AA were older (11.1 vs. 10.0 y) and more likely to be male (69.2% vs. 48.1%) compared with those without AA. Blood tests were performed in 449 (93.3%) children, with higher rates in AA cases (100% vs. 90.4%). Gestalt improved with blood test results, with overall diagnostic accuracy increasing from 65.9% pre-blood tests to 88.5% post-blood tests. Ultrasound (US) was performed in 361 (75.1%) children with a diagnostic accuracy of 90.6% and was frequently used even in patients deemed low-risk post-blood tests (65.7%). One hundred and fifty (31.2%) of suspected AA cases underwent surgery, with 3 negative appendectomies and 1 ovarian cystectomy without appendectomy. Median (IQR) hospital length of stay was significantly longer for AA cases than non-AA cases [50.8 (35.3 to 95.0) h vs. 7.1 (4.6 to 16.8) h]. Conclusions: This study reviews the management and outcomes of suspected AA in a high-volume Australian ED. It shows the importance of blood tests in improving diagnostic accuracy of clinician gestalt and highlights the potential overuse of US in low-risk patients. Future research should explore a more structured diagnostic approach to increase diagnostic accuracy, optimize resource utilization, and improve patient outcomes.
- 12 January 2026
- Published by Wolters Kluwer Health in Pediatric Emergency Care
- Vol. 42 (3) , 209-217
Open AccessSuspected Pediatric Appendicitis Management in the Emergency Department
Objective: Abdominal pain is a common pediatric presentation in the emergency department (ED), and acute appendicitis (AA) is the most common surgical diagnosis. This study describes the management of suspected AA in a tertiary Australian pediatric ED. Methods: A single-center prospective observational study was performed between November 2022 and May 2023. Children aged 5 to 15 years presenting to the ED with acute abdominal pain and clinician suspicion of AA were included. Clinical gestalt was measured using a 5-point Likert Scale before and after blood tests. Diagnosis of AA was confirmed on histopathology, and non-AA was confirmed with follow-up at 30 to 60 days. Results: The study enrolled 481 children; AA was diagnosed in 146 (30.6%). Patients with AA were older (11.1 vs. 10.0 y) and more likely to be male (69.2% vs. 48.1%) compared with those without AA. Blood tests were performed in 449 (93.3%) children, with higher rates in AA cases (100% vs. 90.4%). Gestalt improved with blood test results, with overall diagnostic accuracy increasing from 65.9% pre-blood tests to 88.5% post-blood tests. Ultrasound (US) was performed in 361 (75.1%) children with a diagnostic accuracy of 90.6% and was frequently used even in patients deemed low-risk post-blood tests (65.7%). One hundred and fifty (31.2%) of suspected AA cases underwent surgery, with 3 negative appendectomies and 1 ovarian cystectomy without appendectomy. Median (IQR) hospital length of stay was significantly longer for AA cases than non-AA cases [50.8 (35.3 to 95.0) h vs. 7.1 (4.6 to 16.8) h]. Conclusions: This study reviews the management and outcomes of suspected AA in a high-volume Australian ED. It shows the importance of blood tests in improving diagnostic accuracy of clinician gestalt and highlights the potential overuse of US in low-risk patients. Future research should explore a more structured diagnostic approach to increase diagnostic accuracy, optimize resource utilization, and improve patient outcomes.
- 25 August 2025
- Published by Springer Nature
- p. 543-560
Pediatric Sedation: The Approach in Australia and New Zealand
- 25 August 2025
- Published by Springer Nature
- p. 543-560
Pediatric Sedation: The Approach in Australia and New Zealand
- Open Access
- 8 August 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (10) , 1549-1565
Risk Factors for Severe Bronchiolitis in Australian and Aotearoa New Zealand Infants: A Systematic Review
Aim: Bronchiolitis is the leading cause of hospital admission in Australasian infants. Infants with risk factors for severe disease may have a greater likelihood of prolonged hospitalisation and intensive care admission. This study aimed to synthesise the literature on risk factors for severe bronchiolitis in Australasian infants. Methods: Systematic review including observational studies of risk factors for severe bronchiolitis in Australasian infants (< 12 months), published from 2000. Databases were searched (24 January 2024): MEDLINE, EMBASE, PubMed, Cochrane Library and CINAHL. Risk of bias (RoB) was assessed using the Newcastle–Ottawa Scale for cohort studies, and evidence quality was evaluated using GRADE. Results were narratively synthesised. Results: Ten out of 26 467 articles were included ( N = 895 276; 12 cohorts, prospective = 5, retrospective = 7). Studies were mostly rated low RoB. There was evidence for the following risk factors: younger chronological age, prematurity, plural birth, comorbidity (chronic lung disease, congenital heart disease, chronic neurological disease, any genetic disorder, any comorbidity), Indigenous ethnicity, economic disadvantage, tobacco smoke exposure and timing of illness onset at presentation. Most risk factors had moderate‐quality evidence (range high to very low). Evidence was lacking for the following risk factors present in international literature: breastfeeding exposure and faltering growth. The following risk factors have not been reported in Australasian infants: trisomy‐21, congenital diaphragmatic hernia and environmental pollutants. Conclusions: Risk factors for severe bronchiolitis in Australasian infants are largely consistent with the international literature, although evidence is lacking for some. Knowledge of these risk factors is highly relevant to those assessing infants with bronchiolitis, and in guiding targeted delivery of respiratory syncytial virus immunisation and other preventative programmes. Trial Registration: PROSPERO (CRD42023463917)
- 8 August 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (10) , 1549-1565
Open AccessRisk Factors for Severe Bronchiolitis in Australian and Aotearoa New Zealand Infants: A Systematic Review
Aim: Bronchiolitis is the leading cause of hospital admission in Australasian infants. Infants with risk factors for severe disease may have a greater likelihood of prolonged hospitalisation and intensive care admission. This study aimed to synthesise the literature on risk factors for severe bronchiolitis in Australasian infants. Methods: Systematic review including observational studies of risk factors for severe bronchiolitis in Australasian infants (< 12 months), published from 2000. Databases were searched (24 January 2024): MEDLINE, EMBASE, PubMed, Cochrane Library and CINAHL. Risk of bias (RoB) was assessed using the Newcastle–Ottawa Scale for cohort studies, and evidence quality was evaluated using GRADE. Results were narratively synthesised. Results: Ten out of 26 467 articles were included ( N = 895 276; 12 cohorts, prospective = 5, retrospective = 7). Studies were mostly rated low RoB. There was evidence for the following risk factors: younger chronological age, prematurity, plural birth, comorbidity (chronic lung disease, congenital heart disease, chronic neurological disease, any genetic disorder, any comorbidity), Indigenous ethnicity, economic disadvantage, tobacco smoke exposure and timing of illness onset at presentation. Most risk factors had moderate‐quality evidence (range high to very low). Evidence was lacking for the following risk factors present in international literature: breastfeeding exposure and faltering growth. The following risk factors have not been reported in Australasian infants: trisomy‐21, congenital diaphragmatic hernia and environmental pollutants. Conclusions: Risk factors for severe bronchiolitis in Australasian infants are largely consistent with the international literature, although evidence is lacking for some. Knowledge of these risk factors is highly relevant to those assessing infants with bronchiolitis, and in guiding targeted delivery of respiratory syncytial virus immunisation and other preventative programmes. Trial Registration: PROSPERO (CRD42023463917)
- Open Access
- 20 July 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (8) , 1197-1215
Australasian Bronchiolitis Guideline: 2025 Update
Aim: To provide updated evidence‐based clinical guidance in the management of infants with bronchiolitis presenting to emergency departments (EDs), general paediatric, or intensive care units (ICUs) in Australia and Aotearoa New Zealand (AoNZ) following the first publication in 2016.Method: The Paediatric Research in Emergency Departments International Collaborative (PREDICT) network guideline working group appraised, summarised, and updated evidence from 1 January 2000 to 24 January 2024 addressing 41 questions (30 from the 2016 guideline and 11 new questions for 2025). Recommendations were developed using GRADE methodology and revised after a period of external consultation.Results: The literature search identified 26 467 citations with 431 included in 41 recommendations providing 11 new and 7 key updates. The key changes included: (i) refinement of the clinical features of bronchiolitis, (ii) addition of new risk factors for severity of illness, (iii) advice on the role of biomarkers for unexpected deterioration or admission to ICU, (iv) guidance on glucocorticoids in SARS‐CoV‐2 co‐infection, (v) guidance on combined glucocorticoids/inhaled epinephrine in severe bronchiolitis requiring ICU level care, (vi) refinement of oxygen saturation targets, (vii) guidance on humidified high flow therapy and continuous positive airway pressure, (viii) recommendation on use of RSV prevention therapies/immunisations for babies and mothers.Conclusion: The updated Australasian Bronchiolitis Guideline provides clinicians across Australasian settings with the latest evidence‐based guidance on the management of the commonest condition in infancy requiring hospital admission.
- 20 July 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (8) , 1197-1215
Open AccessAustralasian Bronchiolitis Guideline: 2025 Update
Aim: To provide updated evidence‐based clinical guidance in the management of infants with bronchiolitis presenting to emergency departments (EDs), general paediatric, or intensive care units (ICUs) in Australia and Aotearoa New Zealand (AoNZ) following the first publication in 2016.Method: The Paediatric Research in Emergency Departments International Collaborative (PREDICT) network guideline working group appraised, summarised, and updated evidence from 1 January 2000 to 24 January 2024 addressing 41 questions (30 from the 2016 guideline and 11 new questions for 2025). Recommendations were developed using GRADE methodology and revised after a period of external consultation.Results: The literature search identified 26 467 citations with 431 included in 41 recommendations providing 11 new and 7 key updates. The key changes included: (i) refinement of the clinical features of bronchiolitis, (ii) addition of new risk factors for severity of illness, (iii) advice on the role of biomarkers for unexpected deterioration or admission to ICU, (iv) guidance on glucocorticoids in SARS‐CoV‐2 co‐infection, (v) guidance on combined glucocorticoids/inhaled epinephrine in severe bronchiolitis requiring ICU level care, (vi) refinement of oxygen saturation targets, (vii) guidance on humidified high flow therapy and continuous positive airway pressure, (viii) recommendation on use of RSV prevention therapies/immunisations for babies and mothers.Conclusion: The updated Australasian Bronchiolitis Guideline provides clinicians across Australasian settings with the latest evidence‐based guidance on the management of the commonest condition in infancy requiring hospital admission.
- Open Access
- 17 July 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (8) , 1169-1181
Methodology of the Updated and Expanded Australasian Bronchiolitis Guideline
Background: Bronchiolitis is the most common reason for hospital admission in infants in Australia and Aotearoa New Zealand (AoNZ), with care historically affected by practice variation, including use of ineffective therapies. The Paediatric Research in Emergency Departments International Collaborative (PREDICT) developed the first Australasian (Australia, AoNZ) bronchiolitis guideline in 2016, providing evidence‐based guidance on the management of infants (< 12 months of age), presenting or admitted to hospital with bronchiolitis. In 2022, PREDICT initiated a guideline update to include new evidence and expand the scope to include intensive care (up to intubation), management of SARS‐CoV‐2 co‐infection, and respiratory syncytial virus prevention.Aim: This article outlines the methodology used in the guideline update, following AGREE and CheckUp reporting standards.Methods: A Guideline Advisory Group and Guideline Development Committee, consisting of 29 clinical and methodological experts from Australasia, developed the guideline with consumer input. Forty‐one scoping questions on 25 topics were investigated. Systematic searches were performed by a subject librarian across five electronic databases (last search 24/01/24). Screening of 13,932 new articles occurred independently, in duplicate in two stages. The results of 431 articles were synthesized narratively and quantitatively where appropriate, per topic. Risk of bias was evaluated using appropriate tools. GRADE methodology was used to assess evidence quality and develop the recommendations, which were finalised through consensus voting across three guideline development meetings.Results: The update produced 41 recommendations (33 evidence‐based, 8 consensus‐based; including 11 new and 7 with key revisions), covering bronchiolitis investigations, management and RSV prevention. Interest‐holder groups consulted on the recommendations.Conclusion: The Australasian Bronchiolitis Guideline was updated and expanded according to AGREE and CheckUp reporting standards.
- 17 July 2025
- Published by Wiley in Journal of Paediatrics and Child Health
- Vol. 61 (8) , 1169-1181
Open AccessMethodology of the Updated and Expanded Australasian Bronchiolitis Guideline
Background: Bronchiolitis is the most common reason for hospital admission in infants in Australia and Aotearoa New Zealand (AoNZ), with care historically affected by practice variation, including use of ineffective therapies. The Paediatric Research in Emergency Departments International Collaborative (PREDICT) developed the first Australasian (Australia, AoNZ) bronchiolitis guideline in 2016, providing evidence‐based guidance on the management of infants (< 12 months of age), presenting or admitted to hospital with bronchiolitis. In 2022, PREDICT initiated a guideline update to include new evidence and expand the scope to include intensive care (up to intubation), management of SARS‐CoV‐2 co‐infection, and respiratory syncytial virus prevention.Aim: This article outlines the methodology used in the guideline update, following AGREE and CheckUp reporting standards.Methods: A Guideline Advisory Group and Guideline Development Committee, consisting of 29 clinical and methodological experts from Australasia, developed the guideline with consumer input. Forty‐one scoping questions on 25 topics were investigated. Systematic searches were performed by a subject librarian across five electronic databases (last search 24/01/24). Screening of 13,932 new articles occurred independently, in duplicate in two stages. The results of 431 articles were synthesized narratively and quantitatively where appropriate, per topic. Risk of bias was evaluated using appropriate tools. GRADE methodology was used to assess evidence quality and develop the recommendations, which were finalised through consensus voting across three guideline development meetings.Results: The update produced 41 recommendations (33 evidence‐based, 8 consensus‐based; including 11 new and 7 with key revisions), covering bronchiolitis investigations, management and RSV prevention. Interest‐holder groups consulted on the recommendations.Conclusion: The Australasian Bronchiolitis Guideline was updated and expanded according to AGREE and CheckUp reporting standards.
- Open Access
- 27 June 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e67941
Validation and Comparison of Pediatric Appendicitis Scores and Management Strategies (Project SPASMS): Protocol for a Prospective Multicenter Observational Study
Background: Abdominal pain is a common reason for children to attend the Emergency Department (ED) with acute appendicitis being the most common surgical cause. Various clinical prediction scores (CPSs) have been developed to assist in determining the risk of appendicitis; however, CPSs have been inadequately validated in children and haphazardly adopted in Australia and New Zealand (ANZ) EDs. Objective: This study aims to compare and validate various CPSs for diagnosing pediatric appendicitis in children presenting to ANZ EDs. Methods: This prospective multicenter observational study across 10 ANZ EDs is recruiting children 5-17 years presenting to participating EDs with acute right-sided or generalized abdominal pain lasting ≤7 days and clinician suspicion of appendicitis. CPSs will be calculated by the study team from clinician-recorded data and clinician gestalt recorded on a visual analog scale. Accuracy of CPSs will be assessed by the area under the receiver operating characteristic curve and proportions correctly identified as either low-risk or high-risk based on the CPSs published cutoffs. The final diagnosis of appendicitis will be confirmed on histopathology, and the absence of appendicitis confirmed by telephone, email, or a combination of both to follow up for those discharged directly from ED. Results: This study received funding in July 2023 and started enrolment in August 2023. As of October 2024, we have enrolled and completed follow-up on 1227 participants with an expected end date in mid-2025. Conclusions: This study aims to determine the best-performing CPS for diagnosing pediatric appendicitis in ANZ EDs. Implementation of this CPS in ANZ EDs has the potential to reduce health care costs, rationalize the use of health care resources, and improve the management and outcomes of childhood appendicitis. Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12622001293752; https://tinyurl.com/242wwenx International Registered Report Identifier (IRRID): DERR1-10.2196/67941
- 27 June 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
- Vol. 14 (1) , e67941
Open AccessValidation and Comparison of Pediatric Appendicitis Scores and Management Strategies (Project SPASMS): Protocol for a Prospective Multicenter Observational Study
Background: Abdominal pain is a common reason for children to attend the Emergency Department (ED) with acute appendicitis being the most common surgical cause. Various clinical prediction scores (CPSs) have been developed to assist in determining the risk of appendicitis; however, CPSs have been inadequately validated in children and haphazardly adopted in Australia and New Zealand (ANZ) EDs. Objective: This study aims to compare and validate various CPSs for diagnosing pediatric appendicitis in children presenting to ANZ EDs. Methods: This prospective multicenter observational study across 10 ANZ EDs is recruiting children 5-17 years presenting to participating EDs with acute right-sided or generalized abdominal pain lasting ≤7 days and clinician suspicion of appendicitis. CPSs will be calculated by the study team from clinician-recorded data and clinician gestalt recorded on a visual analog scale. Accuracy of CPSs will be assessed by the area under the receiver operating characteristic curve and proportions correctly identified as either low-risk or high-risk based on the CPSs published cutoffs. The final diagnosis of appendicitis will be confirmed on histopathology, and the absence of appendicitis confirmed by telephone, email, or a combination of both to follow up for those discharged directly from ED. Results: This study received funding in July 2023 and started enrolment in August 2023. As of October 2024, we have enrolled and completed follow-up on 1227 participants with an expected end date in mid-2025. Conclusions: This study aims to determine the best-performing CPS for diagnosing pediatric appendicitis in ANZ EDs. Implementation of this CPS in ANZ EDs has the potential to reduce health care costs, rationalize the use of health care resources, and improve the management and outcomes of childhood appendicitis. Trial Registration: Australian New Zealand Clinical Trials Registry ACTRN12622001293752; https://tinyurl.com/242wwenx International Registered Report Identifier (IRRID): DERR1-10.2196/67941